KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.

Ophthalmol Retina · 2025-Jul · PMID 39914485

Panel B提取完成待 EXE 对齐验证

First CST < 280 µm

Figure 4. Cumulative incidence of ( A ) first absence of IRF and ( B ) first presence of CST <280 μm over 100 weeks. Summaries of time to first absence of diabetic macular edema are Kaplan–Meier estimates, with the time variable defined as the target visit week. P values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P values. Statistics for pairwise comparisons were calculated using a separate model for each comparison. HRs were estimated by Cox regression. a The number of injections includes any active drug administered (faricimab or aflibercept), including medication errors. b Results from stratified analyses are presented for HR and log-rank test versus aflibercept. An HR >1 favors faricimab over aflibercept. c CST was measured as the distance between the internal limiting membrane and Bruch membrane. CI = confidence interval; CST = central subfield thickness; HR = hazard ratio; IRF = intraretinal fluid; Q8W = every 8 weeks; SRF = subretinal fluid; T&E = treat-and-extend.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.58
质量通过是
预期曲线3
实际曲线3
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证32026-07-23T18:05:45+00:00